Zepbound Soars and Lilly Advises Patience on Foundayo

Key Takeaways

• Zepbound generated >$4 B in Q1, up ~80% YoY.
• Mounjaro sales nearly $9 B, more than doubled YoY.
• Lilly lifted full‑year revenue outlook to $85 B.
• Foundayo tablets lag Wegovy launch, but early users are new patients.
• Lilly urges patience, expects oral GLP‑1 to expand obesity market.

Pulse Analysis

The obesity‑treatment wave, led by GLP‑1 agonists, has become a cornerstone of pharmaceutical growth, and Lilly is now a clear beneficiary. After a year of double‑digit gains, the company’s Q1 results showed a 56% revenue surge, largely powered by injectable products Zepbound and Mounjaro. These drugs not only command premium pricing but also tap a rapidly expanding patient pool seeking sustained weight loss, positioning Lilly alongside Novo Nordisk as a dominant force in the market.

Zepbound’s $4 billion haul and Mounjaro’s near‑$9 billion in sales illustrate how injectable GLP‑1 therapies have moved from niche to mainstream. The compounds’ efficacy in both diabetes and obesity has broadened prescriber enthusiasm, driving prescription volumes that outpace analyst expectations. This momentum allowed Lilly to lift its annual revenue forecast to $85 billion, signaling confidence that the obesity segment will continue to fuel top‑line growth despite competitive pressures.

The next frontier for Lilly is oral GLP‑1 therapy, embodied by the newly launched Foundayo tablet. Early prescription data show a slower start compared with Novo Nordisk’s Wegovy pill, but the company highlights that many new users are GLP‑1‑naïve, suggesting market expansion rather than mere substitution. If patient adoption follows the typical diffusion curve, oral formulations could unlock a larger demographic hesitant about injections, ultimately adding a substantial new revenue stream. Lilly’s call for patience reflects a strategic bet that oral obesity drugs will become a pivotal growth engine as awareness and payer coverage mature.